Skip to main content
PAHCPhibro Animal Health CorporatioSell5.8·$31.76-2.07%
Open full analysis

Phibro Animal Health Corporatio (PAHC) Stock Analysis

Range Bound setup

SellVALUE-TRAP 3/5Moderate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Multiple concerning factors at $31.76: Concentration risk — Geographic: United States (57.0%); Concentration risk — Product: Animal Health (74.0%).

Phibro Animal Health is a global animal health and mineral nutrition company marketing approximately 800 product lines in approximately 90 countries to approximately 4,500 customers. Three segments: Animal Health (74% of FY2025 net sales, $963M), Mineral Nutrition (20%), and... Read more

QualityF-score7 / 9FCF yield-1.34%
IncomeYield1.48%(5y avg 2.55%)Payout20.60%sustainable
Stop $29.54Target $39.67(analyst − 13%)A.R:R 2.2:1
Analyst target$45.60+43.6%5 analysts
$39.67our TP
$31.76price
$45.60mean
$58

Sell if holding. Multiple concerning factors at $31.76: Concentration risk — Geographic: United States (57.0%); Concentration risk — Product: Animal Health (74.0%). Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.

Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-09
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Aug 26, 202679d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Attractive valuation
Risks
Concentration risk — Geographic: United States (57.0%)
Concentration risk — Product: Animal Health (74.0%)
Leverage penalty (D/E 2.2): -1.5

Key Metrics

P/E (TTM)13.9
P/E (Fwd)9.7
Mkt Cap$1.3B
EV/EBITDA8.6
Profit Mgn6.3%
ROE30.3%
Rev Growth10.3%
Beta0.46
Dividend1.48%
Rating analysts10

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.25bullish
IV93%elevated

Concentration Risks(10-K Item 1A)

  • HIGHGeographicUnited States57%
    10-K Item 1: 'United States ... _57_| _% _| _57_| _% _| _59_| _%_'
  • HIGHProductAnimal Health74%
    10-K Item 1: 'Animal Health ... _74_| _% _| _69_| _% _| _67_| _%_'

Material Events(8-K, last 90d)

  • 2026-04-14Item 5.02LOW
    Joyce J. Lee resigned from Board of Directors effective April 15, 2026. Resignation was not the result of any disagreement with the Company on any matter relating to operations, policies or practices.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

10 dimensions · all in-band

GatesMomentum 5.5<5.5 (soft — BUY_NOW allowed but watch)Executive change: officer departure/appointmentMomentum 5.5>=4.5A.R:R 2.2 ≥ 1.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
41 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $28.13Resistance $39.68

Price Targets

$30
$40
A.Upside+24.9%
A.R:R2.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Analyst Consensus

Analysts10
Consensus2.5/5
Avg Target$46

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-26 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is PAHC stock a buy right now?

Sell if holding. Multiple concerning factors at $31.76: Concentration risk — Geographic: United States (57.0%); Concentration risk — Product: Animal Health (74.0%). Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $29.54. Score 5.8/10, moderate confidence.

What is the PAHC stock price target?

Take-profit target: $39.67 (+24.9% upside). Prior stop was $29.54. Stop-loss: $29.54.

What are the risks of investing in PAHC?

Concentration risk — Geographic: United States (57.0%); Concentration risk — Product: Animal Health (74.0%); Leverage penalty (D/E 2.2): -1.5.

Is PAHC overvalued or undervalued?

Phibro Animal Health Corporatio trades at a P/E of 13.9 (forward 9.7). TrendMatrix value score: 8.5/10. Verdict: Sell.

What do analysts say about PAHC?

10 analysts cover PAHC with a consensus score of 2.5/5. Average price target: $46.

What does Phibro Animal Health Corporatio do?Phibro Animal Health is a global animal health and mineral nutrition company marketing approximately 800 product lines...

Phibro Animal Health is a global animal health and mineral nutrition company marketing approximately 800 product lines in approximately 90 countries to approximately 4,500 customers. Three segments: Animal Health (74% of FY2025 net sales, $963M), Mineral Nutrition (20%), and Performance Products (6%); total revenue $1.296B. The US represented 57% of FY2025 net sales.

Related stocks: INDV (Indivior Pharmaceuticals, Inc.) · BHC (Bausch Health Companies Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.)
Home Stocks PAHC

Latest news

Latest News

GuruFocus48d ago
StockStory40d ago
The Motley Fool48d ago
TradingView48d ago
Yahoo Finance49d ago
Yahoo Finance34d agoEarnings
Yahoo Finance34d ago
Yahoo Finance42d ago
Investing.com46d ago
TipRanks46d ago
MarketBeat46d ago
Simplywall.st40d ago
TipRanks40d ago
Seeking Alpha37d agoEarnings
MSN35d ago
MSN43d ago
Zacks Investment Research38d agoEarnings
Investing.com South Africa39d ago
GuruFocus45d ago
MSN46d ago
Loading more...